FOXO1 promotes resistance of non-Hodgkin lymphomas to anti-CD20-based therapy

References

• Basso K, Dalla-Favera R. Germinal centres and B cell lymphomagenesis. Nat Rev Immunol. 2015;15:172–84. doi:10.1038/nri3814. PMID:25712152.
   PubMed Web of Science ®Google Scholar
• Dominguez-Sola D, Kung J, Holmes AB, Wells VA, Mo T, Basso K, Dalla-Favera R. The FOXO1 Transcription Factor Instructs the Germinal Center Dark Zone Program. Immunity. 2015;43:1064–74. doi:10.1016/j.immuni.2015.10.015. PMID:26620759.
   PubMed Web of Science ®Google Scholar
• Sander S, Chu VT, Yasuda T, Franklin A, Graf R, Calado DP, Li S, Imami K, Selbach M, Di Virgilio M. PI3 Kinase and FOXO1 Transcription Factor Activity Differentially Control B Cells in the Germinal Center Light and Dark Zones. Immunity. 2015;43:1075–86. doi:10.1016/j.immuni.2015.10.021. PMID:26620760.
   PubMed Web of Science ®Google Scholar
• Szydlowski M, Jablonska E, Juszczynski P. FOXO1 transcription factor: a critical effector of the PI3K-AKT axis in B-cell development. International reviews of immunology. 2014;33:146–57. doi:10.3109/08830185.2014.885022. PMID:24552152.
   PubMed Web of Science ®Google Scholar
• Schmitz R, Young RM, Ceribelli M, Jhavar S, Xiao W, Zhang M, Wright G, Shaffer AL, Hodson DJ, Buras E, et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature. 2012;490:116–20. doi:10.1038/nature11378. PMID:22885699.
   PubMed Web of Science ®Google Scholar
• Pasqualucci L, Khiabanian H, Fangazio M, Vasishtha M, Messina M, Holmes AB, et al. Genetics of follicular lymphoma transformation. Cell Rep. 2014;6:130–40. doi:10.1016/j.celrep.2013.12.027. PMID:24388756.
   PubMed Web of Science ®Google Scholar
• Morin RD, Assouline S, Alcaide M, Mohajeri A, Johnston RL, Chong L, Grewal J, Yu S, Fornika D, Bushell K, et al. Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas. Clinical cancer research: an official journal of the American Association for Cancer Research. 2016;22:2290–300. doi:10.1158/1078-0432.CCR-15-2123. PMID:26647218.
   PubMed Web of Science ®Google Scholar
• Trinh DL, Scott DW, Morin RD, Mendez-Lago M, An J, Jones SJ, et al. Analysis of FOXO1 mutations in diffuse large B-cell lymphoma. Blood. 2013;121:3666–74. doi:10.1182/blood-2013-01-479865. PMID:23460611.
   PubMed Web of Science ®Google Scholar
• Perez-Callejo D, Gonzalez-Rincon J, Sanchez A, Provencio M, Sanchez-Beato M. Action and resistance of monoclonal CD20 antibodies therapy in B-cell Non-Hodgkin Lymphomas. Cancer treatment reviews. 2015;41:680–9. doi:10.1016/j.ctrv.2015.05.007. PMID:26045227.
   PubMed Web of Science ®Google Scholar
• Camicia R, Winkler HC, Hassa PO. Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review. Molecular cancer. 2015;14:207. doi:10.1186/s12943-015-0474-2. PMID:26654227.
   PubMed Web of Science ®Google Scholar
• van Meerten T, van Rijn RS, Hol S, Hagenbeek A, Ebeling SB. Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity. Clinical cancer research: an official journal of the American Association for Cancer Research. 2006;12:4027–35. doi:10.1158/1078-0432.CCR-06-0066. PMID:16818702.
   PubMed Web of Science ®Google Scholar
• Ushmorov A, Leithauser F, Sakk O, Weinhausel A, Popov SW, Moller P, Wirth T. Epigenetic processes play a major role in B-cell-specific gene silencing in classical Hodgkin lymphoma. Blood. 2006;107:2493–500. doi:10.1182/blood-2005-09-3765. PMID:16304050.
   PubMed Web of Science ®Google Scholar
• Sugimoto T, Tomita A, Hiraga J, Shimada K, Kiyoi H, Kinoshita T, Naoe T. Escape mechanisms from antibody therapy to lymphoma cells: downregulation of CD20 mRNA by recruitment of the HDAC complex and not by DNA methylation. Biochem Biophys Res Commun. 2009;390:48–53. doi:10.1016/j.bbrc.2009.09.059. PMID:19769942.
   PubMed Web of Science ®Google Scholar
• Jilani I, O'Brien S, Manshuri T, Thomas DA, Thomazy VA, Imam M, Naeem S, Verstovsek S, Kantarjian H, Giles F, et al. Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia. Blood. 2003;102:3514–20. doi:10.1182/blood-2003-01-0055. PMID:12893761.
   PubMed Web of Science ®Google Scholar
• Beers SA, French RR, Chan HT, Lim SH, Jarrett TC, Vidal RM, Wijayaweera SS, Dixon SV, Kim H, Cox KL, et al. Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood. 2010;115:5191–201. doi:10.1182/blood-2010-01-263533. PMID:20223920.
   PubMed Web of Science ®Google Scholar
• Manshouri T, Do KA, Wang X, Giles FJ, O'Brien SM, Saffer H, Thomas D, Jilani I, Kantarjian HM, Keating MJ, et al. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood. 2003;101:2507–13. doi:10.1182/blood-2002-06-1639. PMID:12446458.
   PubMed Web of Science ®Google Scholar
• Taylor RP, Lindorfer MA. Antigenic modulation and rituximab resistance. Semin Hematol. 2010;47:124–32. doi:10.1053/j.seminhematol.2010.01.006. PMID:20350659.
   PubMed Web of Science ®Google Scholar
• Bobrowicz M, Dwojak M, Pyrzynska B, Stachura J, Muchowicz A, Berthel E, Dalla-Venezia N, Kozikowski M, Siernicka M, Miazek N, et al. HDAC6 inhibition upregulates CD20 levels and increases the efficacy of anti-CD20 monoclonal antibodies. Blood. 2017;130:1628–38. PMID:28830887.
   PubMed Web of Science ®Google Scholar
• Winiarska M, Bil J, Wilczek E, Wilczynski GM, Lekka M, Engelberts PJ, Mackus WJ, Gorska E, Bojarski L, Stoklosa T, et al. Statins impair antitumor effects of rituximab by inducing conformational changes of CD20. PLoS Med. 2008;5:e64. doi:10.1371/journal.pmed.0050064. PMID:18366248.
   PubMed Web of Science ®Google Scholar
• Kennedy AD, Beum PV, Solga MD, DiLillo DJ, Lindorfer MA, Hess CE, Densmore JJ, Williams ME, Taylor RP. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J Immunol. 2004;172:3280–8. doi:10.4049/jimmunol.172.5.3280. PMID:14978136.
   PubMed Web of Science ®Google Scholar
• Bowles JA, Weiner GJ. CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells. J Immunol Methods. 2005;304:88–99. doi:10.1016/j.jim.2005.06.018. PMID:16109421.
   PubMed Web of Science ®Google Scholar
• Szydlowski M, Kiliszek P, Sewastianik T, Jablonska E, Bialopiotrowicz E, Gorniak P, et al. FOXO1 activation is an effector of SYK and AKT inhibition in tonic BCR signal-dependent diffuse large B-cell lymphomas. Blood. 2016;127:739–48. doi:10.1182/blood-2015-06-654111. PMID:26585955.
   PubMed Web of Science ®Google Scholar
• Bojarczuk K, Siernicka M, Dwojak M, Bobrowicz M, Pyrzynska B, Gaj P, et al. B-cell receptor pathway inhibitors affect CD20 levels and impair antitumor activity of anti-CD20 monoclonal antibodies. Leukemia. 2014;28:1163–7. doi:10.1038/leu.2014.12. PMID:24492323.
   PubMed Web of Science ®Google Scholar
• Dybkaer K, Bogsted M, Falgreen S, Bodker JS, Kjeldsen MK, Schmitz A, et al. Diffuse large B-cell lymphoma classification system that associates normal B-cell subset phenotypes with prognosis. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2015;33:1379–88. doi:10.1200/JCO.2014.57.7080. PMID:25800755.
   PubMed Web of Science ®Google Scholar
• Clayton AL, Hazzalin CA, Mahadevan LC. Enhanced histone acetylation and transcription: a dynamic perspective. Mol Cell. 2006;23:289–96. doi:10.1016/j.molcel.2006.06.017. PMID:16885019.
   PubMed Web of Science ®Google Scholar
• Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J, Greenberg ME. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell. 1999;96:857–68. doi:10.1016/S0092-8674(00)80595-4. PMID:10102273.
   PubMed Web of Science ®Google Scholar
• Tang ED, Nunez G, Barr FG, Guan KL. Negative regulation of the forkhead transcription factor FKHR by Akt. The Journal of biological chemistry. 1999;274:16741–6. doi:10.1074/jbc.274.24.16741. PMID:10358014.
   PubMed Web of Science ®Google Scholar
• Zhang X, Yalcin S, Lee DF, Yeh TY, Lee SM, Su J, Mungamuri SK, Rimmelé P, Kennedy M, Sellers R, et al. FOXO1 is an essential regulator of pluripotency in human embryonic stem cells. Nature cell biology. 2011;13:1092–9. doi:10.1038/ncb2293. PMID:21804543.
   PubMed Web of Science ®Google Scholar
• Monsalve M, Olmos Y. The complex biology of FOXO. Current drug targets. 2011;12:1322–50. doi:10.2174/138945011796150307. PMID:21443460.
   PubMed Web of Science ®Google Scholar
• van der Vos KE, Coffer PJ. The extending network of FOXO transcriptional target genes. Antioxidants & redox signaling. 2011;14:579–92. doi:10.1089/ars.2010.3419.
   PubMed Web of Science ®Google Scholar
• Paik JH, Kollipara R, Chu G, Ji H, Xiao Y, Ding Z, et al. FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell. 2007;128:309–23. doi:10.1016/j.cell.2006.12.029. PMID:17254969.
   PubMed Web of Science ®Google Scholar
• Xie L, Ushmorov A, Leithauser F, Guan H, Steidl C, Farbinger J, et al. FOXO1 is a tumor suppressor in classical Hodgkin lymphoma. Blood. 2012;119:3503–11. doi:10.1182/blood-2011-09-381905. PMID:22343918.
   PubMed Web of Science ®Google Scholar
• Birkenkamp KU, Essafi A, van der Vos KE, da Costa M, Hui RC, Holstege F, et al. FOXO3a induces differentiation of Bcr-Abl-transformed cells through transcriptional down-regulation of Id1. The Journal of biological chemistry 2007;282:2211–20. doi:10.1074/jbc.M606669200. PMID:17132628.
   PubMed Web of Science ®Google Scholar
• Myatt SS, Lam EW. The emerging roles of forkhead box (Fox) proteins in cancer. Nature reviews Cancer. 2007;7:847–59. doi:10.1038/nrc2223. PMID:17943136.
   PubMed Web of Science ®Google Scholar
• Vandenberg CJ, Motoyama N, Cory S. FoxO3 suppresses Myc-driven lymphomagenesis. Cell death & disease. 2016;6:e2046. doi:10.1038/cddis.2015.396.
   PubMedGoogle Scholar
• Calnan DR, Brunet A. The FoxO code. Oncogene. 2008;27:2276–88. doi:10.1038/onc.2008.21. PMID:18391970.
   PubMed Web of Science ®Google Scholar
• Ramaswamy S, Nakamura N, Sansal I, Bergeron L, Sellers WR. A novel mechanism of gene regulation and tumor suppression by the transcription factor FKHR. Cancer cell. 2002;2:81–91. doi:10.1016/S1535-6108(02)00086-7. PMID:12150827.
   PubMed Web of Science ®Google Scholar
• Schmidt M, Fernandez de Mattos S, van der Horst A, Klompmaker R, Kops GJ, Lam EW, et al. Cell cycle inhibition by FoxO forkhead transcription factors involves downregulation of cyclin D. Molecular and cellular biology. 2002;22:7842–52. doi:10.1128/MCB.22.22.7842-7852.2002. PMID:12391153.
   PubMed Web of Science ®Google Scholar
• Fernandez de Mattos S, Essafi A, Soeiro I, Pietersen AM, Birkenkamp KU, Edwards CS, et al. FoxO3a and BCR-ABL regulate cyclin D2 transcription through a STAT5/BCL6-dependent mechanism. Molecular and cellular biology. 2004;24:10058–71. doi:10.1128/MCB.24.22.10058-10071.2004. PMID:15509806.
   PubMed Web of Science ®Google Scholar
• Glauser DA, Schlegel W. The FoxO/Bcl-6/cyclin D2 pathway mediates metabolic and growth factor stimulation of proliferation in Min6 pancreatic beta-cells. Journal of receptor and signal transduction research. 2009;29:293–8. doi:10.3109/10799890903241824. PMID:19929250.
   PubMed Web of Science ®Google Scholar
• Nagashima T, Shigematsu N, Maruki R, Urano Y, Tanaka H, Shimaya A, et al. Discovery of novel forkhead box O1 inhibitors for treating type 2 diabetes: improvement of fasting glycemia in diabetic db/db mice. Molecular pharmacology. 2010;78:961–70. doi:10.1124/mol.110.065714. PMID:20736318.
   PubMed Web of Science ®Google Scholar
• Chung S, Lee TJ, Reader BF, Kim JY, Lee YG, Park GY, Karpurapu M, Ballinger MN, Qian F, Rusu L, et al. FoxO1 regulates allergic asthmatic inflammation through regulating polarization of the macrophage inflammatory phenotype. Oncotarget. 2016;7:17532–46. doi:10.18632/oncotarget.8162. PMID:27007158.
   PubMedGoogle Scholar
• Deshaies RJ. Protein degradation: Prime time for PROTACs. Nat Chem Biol. 2015;11:634–5. doi:10.1038/nchembio.1887. PMID:26284668.
   PubMed Web of Science ®Google Scholar
• Zerrouqi A, Pyrzynska B, Brat DJ, Van Meir EG. P14ARF suppresses tumor-induced thrombosis by regulating the tissue factor pathway. Cancer Res. 2014;74:1371–8. doi:10.1158/0008-5472.CAN-13-1951. PMID:24398474.
   PubMed Web of Science ®Google Scholar
• Winiarska M, Bojarczuk K, Pyrzynska B, Bil J, Siernicka M, Dwojak M, Bobrowicz M, Miazek N, Zapala P, Zagozdzon A, et al. Inhibitors of SRC kinases impair antitumor activity of anti-CD20 monoclonal antibodies. mAbs. 2014;6:1300–13. doi:10.4161/mabs.32106. PMID:25517315.
   PubMed Web of Science ®Google Scholar
• Kharas MG, Okabe R, Ganis JJ, Gozo M, Khandan T, Paktinat M, Gilliland DG, Gritsman K. Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice. Blood. 2010;115:1406–15. doi:10.1182/blood-2009-06-229443. PMID:20008787.
   PubMed Web of Science ®Google Scholar